Albert Science International Organization

[1]          N.I. Nii-Trebi, Emerging and neglected infectious diseases: insights, advances, and challenges. Biomed Res Int, 2017, 5245021.

[2]          A. Singh, A. Shaikh, R. Singh, A.K. Singh, COVID-19: From bench to bed side. Diabetes Metab Syndr. 2020, 14: 277-281.

[3]          B. W. Neuman, G. Kiss, A.H. Kunding, D. Bhella, M.F. Baksh, S. Connelly, M.J. Buchmeier,  A structural analysis of M protein in coronavirus assembly and morphology. Journal of Structural Biology, 2011, 174(1), 11–22. https://doi.org/10.1016/j.jsb.2010. 11.021

[4]          D. Schoeman, B.C. Fielding, Coronavirus envelope protein: Current knowledge. Virology Journal, 2019, 16, 69. https://doi.org/10.1186/s12985-019-1182-0

[5]          A. Chafekar, B.C. Fielding, MERS-CoV: Understanding the latest human coronavirus threat. Viruses, 2018, 10(2), 93. https://doi.org/10.3390/ v10020093

[6]          World Health Organization (WHO). WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19–11 March 2020. Available online: https://www.who.int/dg/speeches/detail/who-director-generals- opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed on 19 April 2020).

[7]          L. Ang, H.W. Lee, J.Y. Choi, J. Zhang, M. Soo Lee, Herbal medicine and pattern identification for treating COVID-19: A rapid review of guidelines. Integr. Med. Res, 2020, 9, 100407.

[8]          K.W. Chan, V.T. Wong, S.C.W. Tang, Covid-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative chinese-western medicine for the management of 2019 novel coronavirus disease. Am. J. Chin. Med, 2020, 48, 737–762.

[9]          Y.Q. Wu, L. Zou, X. Yu, D. Sun, S.B. Li,  L. Tang, J.R. Yang, X.Y. Chen, Y.G. Wu, H. Fang, Clinical effects of integrated traditional Chinese and western medicine on COVID-19: A systematic review. Shanghai J. Tradit. Chin. Med, 2020, 1–8.

[10]        G. Qi,  W. Qi,  Q. Jiang,  K.Q. Shen,  X. Zhang,  L. Zhang, The E_cacy of Lianhua Qingwen Combined with Western Medicine Scheme on COVID-19 General Type Patients: A Systematic Review. Clin. J. Tradit. Chin. Med. 2020, 1–9. Available online: http://kns.cnki.net/kcms/detail/34.1268.r.20200410.0909.002.html (accessed on 22 May 2020).

[11]        Z.L. Zhan, J. Liu,  W. Yang,  Y.G. Wang, L.G. Ruan,  P. Huang, L.P. Guo,  Y.J. Bian, S.P. Chen, Y. Chen, et al. Exploratory Study on Evaluation Criteria of Chinese Medicine Treatment of New Coronavirus Pneumonia Based on Case Analysis. J. Tradit. Chin. Med. 2020, 1–11. Available online: http://kns.cnki.net/kcms/detail/11.2166.R.20200312.0949.002.html (accessed on 22 May 2020).

[12]        G. Li, E. de Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov, 2020, 19, 149–150.

[13]        M.P. Lythgoe, et al. Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. Pharmacol. Ther, 2016, 164, 195–203.

[14]        R. Lu, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 2020, 395, 565–574.

[15]        M. Hoffmann, H. Keline-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T.S. Schiergens, G. Herrler, N.H. Wu, A. Nitsche, M.A. Müller, C. Drosten, S. Pöhlman, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 181, (2), 271-280.

[16]        A.C. Walls, Y.J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, D. Veesier, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020, 181, (2), 281-292.

[17]        H. Zhang, J.M. Penninger, Y. Li, N. Zhong, A.S. Slutsky, Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med, 2020, 46, 586–590.

[18]        A. Hussain, B. Bhowmik, N.C. do Vale Moreira, COVID-19 and Diabetes: Knowledge in Progress. Diabetes Res Clin Pract, 2020, 162, 108142.

 [19]       M. Haköksüz, S. K?l?ç, F. Saraç,  Coronaviruses and SARS-COV-2. Turkish J Med Sci, 2020, 50, 459-456.

[20]        J. Shi, Z. Wen, G. Zhong, H. Yang, C. Wang, Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS coronavirus-2. Science, 2020, 368, (6494), 1016-1020.

[21]        WHO Transmission of SARS-CoV-2: implications for infection prevention precautions.https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications for-infection-prevention-precautions (accessed date July 17,2020)

[22]        A. Cortellis, Disease briefing: Coronaviruses. A Clarivate Analytics Solution. www.clarivate.com/cortellis. 16:54 GMT, 14 February, 2020. 81pp

[23]        C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J.  Xu, X. Gu, et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395, (10223), 497–506.

[24]        J.S. Peiris, C.M. Chu, V.C. Cheng, K.S. Chan, I.F.N. Hung, L.L.M. Poon, et al.  Detection of SARS coronavirus in humans and animals by conventional and quantitative (real time) reverse transcription polymerase chain reactions. Methods of Molecular Biology, 2008, 454, 61.

[25]        S.L. Emery, D.D. Erdman, M.D. Bowen, et al. Real-time reverse transcription polymerase chain reaction assay for SARS-associated coronavirus. Emerging Infectious Diseases, 2004, 10, (2), 311.

[26]        M.R. Suresh, P.K. Bhatnagar, D. Das, Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV). Journal of Pharmacology and Pharmaceutical Science, 2008, 11, 1–13.

[27]        G.R. Banik, G. Khandaker, H. Rashid, Middle East respiratory syndrome coronavirus “MERS-CoV”: current knowledge gaps. Journal of Paediatric Respiratory Reviews, 2015, 16, (3), 197–202.

[28]        C. Chakrabotry, A.R. Sharma, G. Sharma, M. Bhattacharya, S.S. Lee, SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci,  2020, 24, (7), 4016-4026.

[29]        F. Song, N. Shi, F. Shan, Z. Zhang, J. Shen, H. Lu, Y. Ling, Y. Jiang, Y. Shi, Emerging coronavirus 2019-nCoV pneumonia. Radiology, 2020, 295, 210-217.

[30]        T. Jefferson, M. Jones, P. Doshi, E.A. Spencer, I. Onakpoya, C.J. Heneghan, Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. British Medical Journal, 2014, 348, 2545.

[31]        J.F. Chan, S.K. Lau, K.K. To, V.C. Cheng, P.C. Woo, K.Y. Yuen, Middle East respiratory syndrome coronavirus: another zoonotic beta-coronavirus causing SARS-like disease. Clinical Microbiological Review, 2015, 28, 465–522.

[32]        D.J. Cleri, A.J. Ricketti, J.R. Vernaleo, Severe acute respiratory syndrome (SARS). Infectious Disease Clinics of North America, 2010, 24, (1), 175.

[33]        Y.H. Hsieh, C.C. King, C.W. Chen, M.S. Ho, S.B. Hsu, Y.C. Wu, Impact of quarantine on the 2003 SARS outbreak: A retrospective modeling study. Journal of Theoretical Biology, 2007, 244, (4), 729.

[34]        H.H. Wong, P. Kumar, F.P.L. Tay, D. Moreau, D.X. Liu, F. Bard, Genome-Wide Screen Reveals Valosin-Containing Protein Requirement for Coronavirus Exit from Endosomes. Journal of Virology, 2015, 89, 11116–11128.

[35]        S.S. Wong, K.Y. Yuen, et al. The management of coronavirus infections with particular reference to SARS. Journal of Antimicrobial Chemotherapy, 2008, 62, (3), 437.

[36]        P.K. Ben Embarek, M.D. Van Kerkhove, Middle East respiratory syndrome coronavirus (MERS-CoV): current situation (three years after the virus was first identified). Weekly Epidemiological Records, 2015, 90, 245–250.

 [37]       Z. Song, Y. Xu, L. Bao, L. Zhang, P. Yu, Y. Qu, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses, 2019, 11, (1), E59.

[38]        W. Zhang, R.H. Du, B. Li, X.S. Zheng, X.L. Yang, B. Hu, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerging Microbes Infections, 2020, 9, (1), 386–389.

[39]        C. Ma, Y. Li, L. Wang, G. Zhao, X. Tao, C.T.K. Tseng,  et al.  Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine, 2014, 32, (18), 2100– 2108.

[40]        C. Schindewolf, V.D. Menachery, et al. Middle East respiratory syndrome vaccine candidates: Cautious optimism. Viruses, 2019, 11, (1), E74.

[41]        N. Cho, Y. Du, A.L. Valenciano,  M.L. Fernández-Murga, M. Goetz, J. Clement, M.B. Cassera, D. Kingston, Antiplasmodial alkaloids from bulbs of Amaryllis belladonna Steud. Bio-organisms and Medicinal Chemistry Letters, 2018, 28, 40–42.

[42]        Q. Li, X. Guan,  P. Wu,  X. Wang,  L. Zhou, Y. Tong, R. Ren, K.S.M. Leung, E.H.Y. Lau, J.Y. Wong, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. The New England Journal of Medicine [epub ahead of print 29 Jan 2020] in press.

[43]        T. Thanh Le, Z. Andreadakis, A. Kumar, et al. The COVID- 19 vaccine development landscape. Nat Rev Drug Discov, 2020, 19, (5), 305-306.  doi: 10. 1038/ d41573- 020- 00073-5

[44]        F. Gao, H.Y. Ou, L.L. Chen, W.X. Zheng, C.T. Zhang, Prediction of proteinase cleavage sites in polyproteins of coronaviruses and its applications in analyzing SARS-CoV genomes. FEBS Letter, 2003, 553, (3), 451–456.

[45]        A. Zumla, J.F. Chan, E.I. Azhar, D.S. Hui, K.Y. Yuen, Coronaviruses - drug discovery and therapeutic options. Nature Reviews Drug Discovery, 2016, 15, (5), 327–47.

[46]        Press release from French National Academy of Medicine (FNAM). Artemisia and COVID 19. Academie Nationale De Medecine, 2020, 20(6), 1-2.

[47]        W. Jing-ke, Plant solutions for the COVID 19 pandemic and beyond: Historical reflections and future perspectives. Molecular plant, 2020, 13, 803-807.

[48]        A. Lin, W.L. Hye, K. Ann, S.L. Myeong, Herbal medicine for the management of COVID 19 during the medical observation period: A review of guidelines. Integrative medicine Research, 2020, 9, 1-5.

[49]        Y, Chen, J. Fan, X.C. Meng, Analysis of the medication rule of Glycyrrhizauralensis-containing antitussive prescriptions based on 2015 edition of Chinesepharmacopoeia (part I). Zhongyi Yaofang, 2020, 31, 281–286.

[50]        S.Y. Xi, Y.W. Gon, Essentials of Chinese materia medica and medical formulas: new century traditional Chinese medicine. 1st ed. Academic Press, 2017.

[51]        X.J. Fu, X.X. Song, L.B. Wei, Z.G. Wang, Study of the distribution patterns of the constituent herbs in classical Chinese medicine prescriptions treating respiratory disease by data mining methods. Chin J Integr Med, 2013, 19, 621–8.

[52]        Q. Shi, Z. Liu, Y. Yang, P. Geng, Y. Zhu, Q. Zhang, et al. Identification of anti-asthmatic compounds in Pericarpium citri reticulatae and evaluation of their synergistic effects. Acta Pharmacol Sin, 2009, 30, 567–575.

[53]        Z. Yu, S. Sun, Y. Guo, Y. Liu, D. Yang, G. Li, et al. Citri Reticulatae Pericarpium(Chen Pi)(Chenpi): botany, ethnopharmacology, phytochemistry, and pharma-cology of a frequently used traditional Chinese medicine. J Ethnopharmacol, 2018, 220, 265–282.

[54]        X.L. Yang, D. Liu, K. Bian, D.D. Zhang, Study on in vitro anti-inflammatory activity of total flavonoids from Glycyrrhizae Radix et Rhizoma (Gan Cao) and its ingredients. Zhongguo Zhong Yao Za Zhi, 2013, 38, 99–104.

[55]        F. Chen, K.H. Chan, Y. Jiang, R.Y.T. Kao, H.T. Lu, K.W. Fan, et al. In vitro susceptibility of10 clinical isolates of SARS coronavirus to selected antiviral compounds. J ClinVirol, 2004, 31, 69–75.

[56]        T. Li, T. Peng, Traditional Chinese herbal medicine as a source of molecules with antiviral activity. Antiviral Res, 2013, 97, 1–9.

[57]        R. Yang, L. Wang, B. Yuan, Y. Liu, The pharmacological activities of licorice. Planta Med, 2015, 81, 1654–69.

[58]        L. Luo, J. Jian, C. Wang, M. Fitzgerald, W. Hu, Y. Zhou, et al. Analysis on herbalmedicines utilized for treatment of COVID-19. Acta Pharm Sinica B 2020, http://dx.doi.org/10.1016/j.apsb.2020.05.007.

[59]        M.L. Salem, M.S. Hossain, Protective effect of black seed oil from Nigella sativa against murine cytomegalovirus infection. International Journal of Immunopharmacology, 2000, 22, 729–740.

[60]        C.A. Erdelmeier,  J. Cinatl, H. Rabenau, H.W. Doerr, A. Biber,  E. Koch, Antiviral and antiphlogistic activities of Hamamelis virginiana bark. Planta Medica, 1996, 62, 241–245.

[61]        W. Yoshida, K. Sode, K. Ikebukuro, Homogeneous DNA sensing using enzyme-inhibiting DNA aptamers. Journal of Biochemistry and Biophysics Research Communication, 2006, 348, 245–252.

[62]        P. Schnitzler, K. Schon, J. Reichling, Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture. Die Pharmazie, 2001, 56, 343–347.

[63]        S.D. Cox, C.M. Mann, J.L. Markham, Interactions between components of the essential oil of Melaleuca alternifolia. Journal of Applied Microbiology, 2001, 91, 492–497.

[64]        A. Pieroni, Medicinal plants and food medicines in the folk traditions of the upper Lucca Province, Italy. Journal of Ethnopharmacology, 2000, 70, 235–273.

[65]        A. De Logu, G. Loy, M.L. Pellerano,  L. Bonsignore, M.L. Schivo, Inactivation of HSV-1 and HSV-2 and prevention of cell-to-cell virus spread by Santolina insularis essential oil. Antiviral Research, 2000, 48, 177–185.

[66]        S.A.A. Jassim, M.A. Naji, The Society for Applied Microbiology. Journal of Applied Microbiology, 2003, 95, 412–427.

[67]        M. Premanathan, R. Arakaki, H. Izumi, K. Kathiresan, M. Nakano, N. Yamamoto, H. Nakashima, Antiviral properties of a mangrove plant, Rhizophora apiculata Blume, against human immunodeficiency virus. Antiviral Research, 1999, 44, 113–122.

[68]        M, Premanathan, K. Kathiresan, N. Yamamoto, H. Nakashima, In vitro anti-human immunodeficiency virus activity of polysaccharide from Rhizophora mucronata Poir. Journal of Bioscience, Biotechnology and Biochemistry, 1999, 63, 1187–1191

[69]        C.J. Gauntt, H.J. Wood, H.R. McDaniel, B.H. McAnalley, Aloe polymannose enhances anti-coxsackievirus antibody titres in mice. Phytotherapy Research, 2000, 14, 261–266

[70]        Y.M. Lin, M.T. Flavin, R. Schure, F.C. Chen, R. Sidwell, D.L. Barnard, J.H. Huffman, E.R.  Kern, Antiviral activities of biflavonoids. Planta Medica, 1999, 65, 120–125.

[71]        N. Bunyapraphatsara, S. Dechsree, C. Yoosook, A. Herunsalee, Y. Panpisutchai,  Anti-herpes simplex virus component isolated from Maclura cochinchinensis. Journal of Phytomedicine, 2000, 6, 421–424.

[72]        R. Pal, S.K. Phadada,  Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract,  2020, 163, 108146.

[73]        M. Gendrot, E. Javelle, A. Clerc,  H. Savini, B. Pradines,  Chloroquine as a prophylactic agent against COVID-19? Int J Antimicrob Agents, 2020, 55, (6), 105980.

[74]        M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong, G. Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30, (3), 269-71.

[75]        A. Brufsky, Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic. J Med Virol, 2020, 92, 770–775.

[76]        H. Shiratori, C. Feinweber, S. Luckhardt, N. Wallner, G. Geisslinger, A. Weigert, M.J. Parnham, An in vitro test system for compounds that modulate human inflammatory macrophage polarization. Eur J Pharmacol, 2018, 833, 328-338.

[77]        L.R. Rekedal, E. Massarotti, R. Garg, R. Bhatia, T. Gleeson, B. Lu, D.H. Solomon, Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum, 2010, 62, (12), 3569-3573.

[78]        J. Gao, Z. Tian, X. Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BiosciTrends, 2020, 14, (1), 72 73.

[79]        P. Gautret, J.C. Lagier, P. Parola, V.T. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giodanengo, V.E. Vieira, H.T. Dupont, S. Honore,  P. Colson,  E. Chabriere, B. La Scola, J.M. Rolain, P. Brouqui,  D. Raoult,  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020, 105949.

[80]        Z. Chen, J. Hu, Z. Zhang, S. Jiang, S. Han, D. Yan, R. Zhuang, B. Hu, Z.  Zhang, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv, 2020.

[81]        X. Yao, F. Ye, M. Zhang, C. Cui, B. Huang, P. Niu, X. Liu, L. Zhao, E. Dong, C. Song, S. Zhan, R. Lu, H. Li, W. Tan, D. Liu, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus2 (SARS-CoV-2). Clin Infect Dis, 2020, 71, (15), 732-739.

[82]        P. Colson, J.M. Rolain, J.C. Lagier, P. Brouqui, D. Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents, 2020, 55, (4), 105932.

[83]        J.M. Sanders, M.L. Monogue, T.Z. Jodlowski, J.B. Cutrell, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review. JAMA, 2020, 323, (18), 1824-1836.

[84]        A.C. Kalil, Treating COVID-19—off-labe ldrug use, compassionate use, and randomized clinical trials during pandemics. JAMA, 2020, 323, (19), 1897-1898.

[85]        W. Ahsan, S. JAved, M. Al Bratty, H.A. Alhazmi, A. Najmi, Treatment of SARS-CoV-2: How far have we reached? Drug Discov Ther, 2020, 14(2), 67-72.

[86]        M. Jacobs, A. Rodger, D.J. Bell, S. Bhagani, L. Cropley, A. Filipe, R.J. Gifford, S. Hopkins, J. Hughes, F. Jabeen, I. Johannessen, D. Karageorgopoulos, A. Lackenby, R. Leste, R.S.N. Liu, A. MacConnachie, T. Mahungu, D. Martin, N. Marshall, S. Mepham, R. Orton, M. PAlmarini, M. Patel, C. Perry, S.E. Peters, D. Porter, D. Ritchie, N.D. Ritchie, R.A. Seaton, V.B. Sreenu, K. Templeton, S. Warren, G.S. Wilkie, M. Zambon, R. Gopal, E.C. Thomson, Late Ebola virus relapse causing meningo encephalitis:a case report. Lancet, 2016, 388, (10043), 498-503.

[87]        Z. Wang, B. Yang, Q. Li, L. Wen, R. Zhang, Clinical Features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis, 2020, 71(15), 769-777.

[88]        C.M. Chu, V.C.C. Cheng, I.F.N. Hung, et al. Role of lopinavir/ ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 2004, 59(3), 252-256. doi: 10. 1136/ thorax. 2003. 012658

[89]        K. Kupferschmidt, J. Cohen, Race to find COVID-19 treatments accelerates. Science, 2020, 367(6485), 1412-1413. doi: 10. 1126/ science. 367. 6485. 1412

[90]        National Health Commission and State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia. Chin Med J. 2020, 133, 1087–1095.

[91]        J.F. Rossignol,  Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. Journal of infection and public health, 2016, 9(3), 227-230.

[92]        J. Haffizulla, A. Hartman, M. Hoppers, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. The Lancet Infectious diseases, 2014, 14(7), 609-618.

[93]        A.E. Gamino-Arroyo, M.L. Guerrero, S. McCarthy, et al. Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2019, 69(11), 1903-1911.

[94]        C. Kotch, D. Barrett, D.T. Teachey, Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert review of clinical immunology, 2019, 15 (8), 813-822.

[95]        D.W. Lee, B.D. Santomasso, F.L. Locke, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 2019, 25 (4), 625-638.

[96]        J.H. Park, F.A. Romero, Y. Taur, et al. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2018, 67(4), 533-540.

[97]        R.Q. Le, L.  Li, W. Yuan, et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. The oncologist, 2018, 23(8), 943-947.

[98]        M.E. Peter, Medicinal plants, synthetic drugs or clinical therapy: the safest option against the pandemic COVID 19 coronavirus, 2020, 5(3), 1-13.

[99]        E.L. Tan, E.E. Ooi, C.Y. Lin, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging infectious diseases, 2004, 10(4), 581-586.

[100]      R.U. Kadam, I.A. Wilson, Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad SciUSA, 2017, 114(2), 206-214.

[101]      Q. Cai, M. Yang, D. Liu, Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering, 2020.